Akynzeo | Prevent Nausea and Vomiting | HongKong DengYue Medicine

Akynzeo Application Scope

A fixed-dose combination antiemetic used to prevent chemotherapy-induced nausea and vomiting.

Characteristics

• Ingredients:

  • 300 mg of netupitant

  • 0.5 mg of palonosetron

• Properties: A selective neurokinin-1 (NK₁) receptor antagonist.​

• Packaging Specification: Available as a single-dose capsule in a blister pack.​

• Storage: Store capsules at room temperature, between 20°C to 25°C (68°F to 77°F).​

• Expiry Date: ​Refer to the packaging for the specific expiration date.

• Executive Standard: ​Approved under FDA New Drug Application (NDA) 205718.

• Approval Number: FDA approval granted on October 10, 2014.

• Date of Revision: ​February 2023.

• Manufacturer:Helsinn Therapeutics (U.S.), Inc.

Guidelines for the Use of Ensartinib

• Dosage and Administration:

  • Capsules: One capsule (300 mg netupitant/0.5 mg palonosetron) taken orally approximately 1 hour before the start of chemotherapy.

  • Injection: Administered intravenously over 30 minutes, starting 30 minutes before chemotherapy.

• Adverse Reactions: Common side effects include headache, fatigue, constipation, and erythema.

• Contraindications: None known.

• Precautions:

  • Hypersensitivity reactions, including anaphylaxis, have been reported with palonosetron.

  • Serotonin syndrome has been reported, especially with concomitant use of serotonergic drugs.​

Interactions

• Drug Interactions:

  • Netupitant is a moderate inhibitor of CYP3A4; avoid concomitant use with strong CYP3A4 inducers or substrates.

  • Dexamethasone doses should be reduced when given with Akynzeo.

  ​

• Generic Name/Brand Name: Netupitant and palonosetron / Akynzeo
• Indications: Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including highly emetogenic chemotherapy.
• Dosage Form: ​Oral capsule
• Specification: 300 mg netupitant / 0.5 mg palonosetron, capsules

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.